Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 11/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3743588 | 1.00 | HTR2A (0.43) | HTR2AHTR2CHTR2BDPP4TSHR | |
| SCHEMBL3743597 | 1.00 | HTR2A (0.43) | HTR2AHTR2CHTR2BDPP4TSHR | |
| SCHEMBL3743674 | 0.88 | DPP4 (0.40) | HTR2AHTR2CHTR2BDPP4TSHR | |
| SCHEMBL3743668 | 0.88 | DPP4 (0.40) | HTR2AHTR2CHTR2BDPP4TSHR | |
| SCHEMBL3743670 | 0.88 | DPP4 (0.40) | HTR2AHTR2CHTR2BDPP4TSHR | |
| SCHEMBL3750797 | 0.81 | DPP4 (0.34) | HTR2AHTR2CHTR2BDPP4MEN1 | |
| SCHEMBL3750791 | 0.81 | DPP4 (0.34) | HTR2AHTR2CHTR2BDPP4MEN1 | |
| SCHEMBL3750793 | 0.81 | DPP4 (0.34) | HTR2AHTR2CHTR2BDPP4MEN1 | |
| SCHEMBL3740545 | 0.80 | DPP4 (0.53) | DPP4MEN1KMT2A | |
| SCHEMBL3740553 | 0.80 | DPP4 (0.53) | DPP4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1919854-B1 | PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) | ABBVIE INC (US) | 2013-09-18 | — | — | EP | disclosed |
| US-7834012-B2 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBOTT LABORATORIES (US) | 2010-11-16 | — | — | US | disclosed |
| US-20070049596-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBVIE INC. | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049596-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | DPP4, DPP3, DPP7 | HTR2A 2636/4885HTR2C 3324/4885HTR2B 3159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.